Skip to main content

Ensysce Biosciences, Inc.

ENSC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001716947

In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Ensysce Biosciences, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of ENSC: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders17115−1
Shares502.6K36.7K487.0K+21.1K (+4.5%)
Value$461.1K$33.8K$261.5K−$165.9K (−38.8%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Ensysce Biosciences, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to ENSC in Q1 2026
InstitutionSharesValue% of portfolio
Citadel Advisors LLC57,363$30.9K0.00%
XTX Topco Ltd24,363$13.1K0.00%
Vanguard Fiduciary Trust Co23,854$12.9K0.00%
Jane Street Group, LLC13,570$7.31K0.00%
Virtu Financial LLC13,313$7.00K0.00%
Vanguard Capital Management LLC12,854$6.93K0.00%

Sold out (7)

Institutions that held Ensysce Biosciences, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of ENSC in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
DRW Securities, LLC98,481$90.6K
Financial Plan, Inc.24,000$22.1K
HRT Financial LP24,491$22.0K
Two Sigma Securities, LLC21,605$19.9K
Williams & Novak, LLC17,850$16.4K
Bank of America Corp72$66
Jones Financial Companies LLLP41$38

Not filed for Q1 2026 yet (1)

Institutions that held Ensysce Biosciences, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ENSC in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc36,708$33.8K